ANNEXON INC (ANNX)
Health Care · Neuroinflammation and complement-targeted biopharmaceuticals · NASDAQ
Annexon is a clinical-stage biotechnology company developing C1q-inhibitor therapies to treat neurodegenerative and autoimmune diseases driven by the classical complement pathway.
What ANNEXON INC does
Annexon is a clinical-stage biopharmaceutical company developing product candidates for use in treating severe acute neurological and autoimmune disorders. The company's pipeline is focused on complement pathway modulation, a key mechanism underlying inflammation in neurological conditions. Annexon is advancing multiple candidates through clinical development with the goal of addressing patient populations with limited therapeutic options.
Themes: Neuroinflammation, Complement pathway inhibition, Autoimmune disorders, Clinical-stage biotech
Fundamentals
- Price$5.07 as of 2026-08-21 close
- Market cap$856M as of 2026-08-24
- 1-year return+133.6% 2025-08-21 close $2.17 → 2026-08-21 close $5.07
- P/En/a earnings data not available
- ROE-101.2% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta1.28 as of 2026-08-24
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How ANNX compares in its sector
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ANNEXON INC looks technically
ANNEXON INC (ANNX) is trading 3.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 208 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 11, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative). It made a new 20-day low about 18 trading days ago. It is 29.4% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 4% of the past ~6 months), which often precedes a bigger move. Trading volume is unusually light — only about 47% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 3.6% below its 200-day average, the long-term trend line — a long-term downtrend | -3.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $5.36 | $5.36 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $5.26 | $5.26 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 5. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 208 trading days ago — a "golden cross", a bullish long-term signal | 208 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 11, below the 25 that marks a real trend) | 10.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30) | 43.8 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($5.00 to $5.70) — its "stochastic" reading is 10 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 10.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $7.18 | $7.18 |
|---|---|---|
| From the 52-week high | it is 29.4% below its 52-week high (its highest price of the past year) | -29.4% |
| Above the 52-week low | it is 149.8% above its 52-week low (its lowest price of the past year) | +149.8% |
| Below the 52-week high | it is 29.4% below its highest point of the past year | 29.4% |
| Since a 20-day breakout | it made a new 20-day low about 18 trading days ago | 18 sessions |
| Since a 55-day breakout | it made a new 55-day high about 28 trading days ago | 28 sessions |
| All-time high | its highest closing price on record is $38.01 (set on 2021-02-22) | $38.01 |
| Given back of the 52-week move | over the past year its closes ranged ($2.05 to $6.96), and it has given back roughly a third of its rise from last year’s low — 38% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.77 to $3.93. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 38.5% |
| From the all-time high | it is 86.7% below its all-time high | -86.7% |
| Nearest price level | it is trading 0.8% above a support level at $5.03 — a price it turned at four times since 2024-11-20, most recently on 2026-08-12. Since 2024-08-21 it has 9 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.8% |
| All-time low | its lowest closing price on record is $1.28 (set on 2025-04-10) | $1.28 |
| Above the all-time low | it is 294.6% above its all-time low | +294.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 4% of the past ~6 months), which often precedes a bigger move | 4th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.328 between its high and its low — about 6.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.328 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $4.91 and $5.60 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $4.91 – $5.25 – $5.60 |
| Typical daily range (% of price) | its price moves about 6.5% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.5% |
| Stretch from the 200-day average | it is trading 0.6 daily ranges below its 200-day average price (3.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.6 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 47% of its 30-day average | 0.47× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 11.1% since the prior reading | +11.1% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.10 toward buy |
Candlestick patterns
2
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 1.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.2% |
|---|---|---|
| Gap filled | a 3.2% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -7.82% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 8.3 percentage points (the stock lost 5.9% while the market gained 2.3%) | -8.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 9.9 percentage points (the stock lost 6.8% while the market gained 3.1%) | -9.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 7.6 percentage points (the stock gained 3.5% while the market gained 11.1%) | -7.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 113.2 percentage points (the stock gained 133.6% while the market gained 20.5%) | +113.2% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 8.2% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.6% of the share price. | -8.2% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 9% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $5.57 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -9.0% |
|---|
Price levels it has turned at before
ANNX last closed at $5.07 on 2026-08-21. Since 2024-08-21 it has turned at 9 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $5.03 | Support | 0.8% below the last close | turned there four times · 2024-11-20 to 2026-08-12 |
| $4.84 | Support | 4.4% below the last close | turned there twice · 2026-03-30 to 2026-05-19 |
| $5.32 | Resistance | 4.8% above the last close | turned there three times · 2024-09-04 to 2026-05-07 |
| $4.76 | Support | 6.0% below the last close | turned there three times · 2025-12-16 to 2026-07-29 |
| $5.51 | Resistance | 8.8% above the last close | turned there twice · 2024-12-02 to 2025-12-22 |
| $5.71 | Resistance | 12.6% above the last close | turned there four times · 2024-10-01 to 2026-08-07 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $5.00.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 6 trading days, since 2026-08-14.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · Analyst price target recently RAISED | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · bollinger bands · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.60 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$14.71 range $7.00 – $27.00; median $12.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ANNX
- Consensus EPS estimate-$0.2431 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical development and regulatory approval risk; the company is primarily focused on clinical-stage candidates with uncertain outcomes and timelines for regulatory approval","Limited operating history and substantial accumulated deficit; the company has generated net losses every period and has accumulated deficit of approximately $961.5 million as of Q1 2026","Dependency on continued financing; the company has limited cash runway and will require additional capital raises to fund ongoing clinical development and operations"]
What changed in the latest 10-Q
AI-assisted comparison of ANNX's 10-Q filed 2026-05-07 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to 'unaudited condensed consolidated financial statements' in newer filing (2026-05-07)
- Reference to 'Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission, or the SEC, on March 30, 2026' in newer filing
- Statement that 'Our Marketing Authorization Application, or MAA, filed with the European Medicines Agency, or EMA, in January 2026 for tanruprubart for the treatment of GBS is under review' in newer filing
- Reference to 'FORWARD study' providing 'initial pharmacokinetics, or PK, pharmacodynamics, or PD, biomarker and functional data in 2026' in newer filing
- Statement about plan to 'engage with the FDA with the goal of reaching alignment on our current and supplemental data package and information supporting the generalizability of tanruprubart in Western patients for submission of a biologics license application, or BLA, in 2026' in newer filing
- Statement that vonaprument is 'the only investigational therapy in GA to show significant vision preservation on assessments of best corrected visual acuity, or BCVA, and low luminance visual acuity' (without 'or LLVA' acronym) in newer filing
- Reference to 'EZ loss' as 'a key anatomic measure of photoreceptor health and function' in newer filing
- Statement that 'We plan to report topline data in the fourth quarter of 2026' for ARCHER II in newer filing
- Reference to 'The single-study program will be analyzed as two sub-studies in the U.S. in accordance with the FDA's two-trial recommendation' in newer filing
- Reference to EMA's 'Product Development Coordinator Pilot launched in July 2025' in newer filing
- Truncated text ending at 'In a Phase 1 single-ascending dose and multiple-ascending dose clinica' in newer filing
- Removed:
- Reference to 'consolidated financial statements' without 'unaudited condensed' qualifier in older filing
- Reference to 'Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission, or the SEC, on March 3, 2025' in older filing
- Detailed explanation of company's proprietary platform and approach to targeting C1q in older filing
- References to 'three therapeutic areas—autoimmune, neurodegeneration and ophthalmology' and three priority programs structure in older filing
- References to 'Real-World Evidence, or RWE, indirect comparison data' and 'drug-drug interaction safety data' in older filing
- Statement that 'Completed placebo-controlled studies were conducted in Southeast Asia given GBS' sudden and debilitating disease course and lack of approved comparator in the U.S.' in older filing
- Statement that 'Productive regulatory interactions with European Rapporteurs and the Pediatric Committee of the European Medicines Agency reaffirmed the current data package is on track for our Marketing Authorization Application, or MAA, submission expected in January 2026' in older filing
- Statement that 'Dialogue with FDA is ongoing regarding the generalizability package supporting the BLA submission' in older filing
- Reference to 'dry AMD with GA' (replaced with just 'GA') in newer filing
- Statement about 'assuming positive Phase 3 results' in older filing
- Reference to reporting 'topline data in the second half of 2026' in older filing (changed to 'fourth quarter of 2026')
- Partial reference to 'Priority' designation discussion at end of older filing text
- Reworded:
- Overview section changed from detailed platform explanation to streamlined statement about company advancing 'next generation platform of targeted immunotherapies aimed at complement-mediated neuroinflammatory diseases that impact nearly 10 million people worldwide' in newer filing
- Strategic priorities statement added as distinct paragraph in newer filing
- Tanruprubart description reorganized: moved from bullet point structure to narrative format in newer filing
- Reference to MAA submission changed from 'expected in January 2026' (older) to 'filed with the European Medicines Agency, or EMA, in January 2026 for tanruprubart for the treatment of GBS is under review' (newer)
- ARCHER II primary endpoint wording changed from 'prevention of ≥15-letter loss of BCVA' (older) to 'measuring proportion of patients with confirmed BCVA ≥15-letter loss at any two consecutive visits through month 15' (newer)
- Secondary endpoint for ARCHER II changed from 'prevention of ellipsoid zone, or EZ, loss' (older) to 'EZ loss, which is a key anatomic measure of photoreceptor health and function' (newer)
- Vonaprument description changed from 'dry AMD with GA' (older) to 'GA' alone in newer filing opening
- Description of GA indication changed from 'dry AMD with GA' to simply 'GA, a leading cause of blindness' in newer filing
- Notes:
- Newer filing MD&A section appears truncated at 'In a Phase 1 single-ascending dose and multiple-ascending dose clinica' suggesting incomplete text capture
- Older filing text also appears truncated at end of vonaprument discussion 'Vonaprument is the first and only therapeutic candidate for the treatment of GA to receive Priority' preventing full comparison of that section
Risk Factors
- Added:
- Risk Factors section page number changed from 28 (2025-11-10) to 25 (2026-05-07)
- Item 2 page number changed from 72 (2025-11-10) to 69 (2026-05-07)
- Item 3 page number changed from 72 (2025-11-10) to 69 (2026-05-07)
- Item 4 page number changed from 72 (2025-11-10) to 69 (2026-05-07)
- Item 5 page number changed from 72 (2025-11-10) to 69 (2026-05-07)
- Item 6 page number changed from 73 (2025-11-10) to 70 (2026-05-07)
- SIGNATURES page number changed from 74 (2025-11-10) to 71 (2026-05-07)
- Balance sheet dated March 31, 2026 and December 31, 2025 (newer filing) versus September 30, 2025 and December 31, 2024 (older filing)
- Cash and cash equivalents increased to $175,208 thousand as of March 31, 2026 versus $139,419 thousand as of September 30, 2025
- Short-term investments decreased to $49,817 thousand as of March 31, 2026 versus $49,302 thousand as of September 30, 2025
- Total assets decreased to $262,888 thousand as of March 31, 2026 versus $229,142 thousand as of September 30, 2025
- Accumulated deficit increased (more negative) to $(961,531) thousand as of March 31, 2026 versus $(869,133) thousand as of September 30, 2025
- Common stock shares increased to 162,501,717 as of March 31, 2026 versus 115,122,582 as of September 30, 2025
- Three months ended March 31 comparison (2026 vs 2025) in statements of operations instead of three and nine months ended September 30 (2025 vs 2024)
- Net loss per share was $(0.23) for Q1 2026 versus $(0.37) for Q1 2025
- Weighted-average shares increased to 194,200,100 for Q1 2026 versus 148,108,809 for Q1 2025
- Statements of stockholders' equity show activity through March 31, 2026 and March 31, 2025 versus through September 30, 2025 and September 30, 2024 in older filing
- Issuance of common stock activity noted in Q1 2026 period ($32,694 thousand) with 6,049,762 shares issued
- Exercise of pre-funded warrants activity noted in Q1 2026 period (6,526,508 warrants)
- Cash flow statements cover three months ended March 31, 2026 and 2025 versus nine months ended September 30, 2025 and 2024
- Net cash used in operating activities was $(46,796) thousand for Q1 2026 versus $(50,055) thousand for Q1 2025
- Removed:
- Nine months ended September 30 comparison data removed (older filing showed both three months and nine months)
- Deemed dividend on modification of common stock warrants line item removed from statements of operations
- Net loss attributable to common stockholders line item removed from statements of operations
- Nine months ended September 30 operating results data removed
- Stockholders' equity table showing June 30, 2025 intermediate period balances removed
- Stockholders' equity table showing multiple 2024 quarterly periods (March 31, June 30, September 30) removed
- Nine months ended September 30 cash flow statement data removed
- Reworded:
- Column header changed from 'Accumulated Other Comprehensive (loss) income' to 'Accumulated Other Comprehensive Loss' in balance sheet
- Balance sheet comparison dates changed from September 30, 2025 and December 31, 2024 to March 31, 2026 and December 31, 2025
- Statements of operations changed from comparing 'Three Months Ended September 30' and 'Nine Months Ended September 30' to only 'Three Months Ended March 31'
- Comprehensive loss statements changed from comparing September 30 periods to March 31 periods
- Notes:
- The older filing (2025-11-10) is a Q3 2025 10-Q with data through September 30, 2025, while the newer filing (2026-05-07) is a Q1 2026 10-Q with data through March 31, 2026, representing different reporting periods rather than revisions of the same period
- The financial statement differences primarily reflect the passage of six months and normal business operations rather than restatements
- Text appears truncated in both filings at the end of the provided excerpts, preventing full comparison of all content
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 0 open-market sales by insiders in the last 90 days.
- Last 90 days1 buy ($3M) · 0 sells — 1 buying insider
- Last 180 days4 buys ($3M) · 1 sell ($31603) — 2 buying, 1 selling insiders
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-05-28. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ANNX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ANNX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 29,925,047
- Reported value $165,784,762
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ANNX had 30,772,146 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for ANNX because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 30,772,146
- Prior settlement (shares) 29,827,889
- Reported change 3.17%
- Days to cover (reported) 10.45
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Alexion Pharmaceuticals (AZN)
- Apellis Pharmaceuticals (APLS)
- UCB (UCBJF)
- BioCryst Pharmaceuticals (BCRX)
- Alnylam Pharmaceuticals (ALNY)
- Roche (RHHBY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ANNX vs…
ANNEXON INC is found in…
Frequently asked questions
What does ANNEXON INC (ANNX) do?
Annexon is a clinical-stage biopharmaceutical company developing product candidates for use in treating severe acute neurological and autoimmune disorders. The company's pipeline is focused on complement pathway modulation, a key mechanism underlying inflammation in neurological conditions. Annexon is advancing multiple candidates through clinical development with the goal of addressing patient populations with limited therapeutic options.
What sector is ANNEXON INC (ANNX) in?
ANNEXON INC (ANNX) is classified in the Health Care sector. Its industry is Neuroinflammation and complement-targeted biopharmaceuticals. It trades on NASDAQ.
Who are ANNEXON INC's (ANNX) competitors?
Notable peers of ANNEXON INC (ANNX) include Alexion Pharmaceuticals, Apellis Pharmaceuticals, UCB, BioCryst Pharmaceuticals and Alnylam Pharmaceuticals. This peer set is informational only — not financial advice.
Is ANNEXON INC (ANNX) overbought or oversold right now?
ANNEXON INC (ANNX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 44, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ANNX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.